

TRANSITIONING TO A GENERIC:

Preparing for Generic Glycerol Phenylbutyrate



WHAT CHANGE IS COMING FOR PATIENTS CURRENTLY TAKING RAVICTI® (glycerol phenylbutyrate)?

As early as July, generic glycerol phenylbutyrate is expected to become available.

Note that this timing may shift; Amgen does not control the timing of generic medicine availability.



It is important for patients

to be aware of this potential change because we expect that over time, insurance companies will require them all to move to one of the generic medicines.



Amgen will continue to provide patient support for those taking RAVICTI.



Generic medicines

approved by the US Food and Drug Administration (FDA) work the same way and provide the same clinical benefit as the brand-name medication. Generic medicines may have minor differences that do not affect efficacy or safety and come in different packaging.

Amgen will provide information and updates to the community during these changes.

Dear Community,

We are writing to inform you of a potential change for patients taking RAVICTI® (glycerol phenylbutyrate). As early as July 1, 2025, generic glycerol phenylbutyrate is expected to become available, providing additional medicine options to physicians and patients. Note that this timing may shift; Amgen does not control the timing of generic medicine availability.

There is no action required at this time; however, it is important for you or your loved one to be aware of this potential change as we expect that over time, insurance companies will require patients to switch to generic glycerol phenylbutyrate.

Generic medicines approved by the US Food and Drug Administration (FDA) work the same way and provide the same clinical benefit as the brand-name medication. Generic medicines may have minor differences that do not affect efficacy and safety but do come in different packaging.

In the coming weeks, your Amgen Patient Access Liaison (PAL) will be reaching out to provide resources and further information. Amgen is committed to providing you and the healthcare community updates as they become available.

If you have any questions in the meantime, please don't hesitate to contact your dedicated PAL or me.

Sincerely,

Jason Riley

General Manager

Ultra-Rare Medicines

rareconnect@amgen.com

Estimada comunidad:

Les escribimos para informarles de un posible cambio para los pacientes que toman RAVICTI® (fenilbutirato de glicerol). Se espera que el fenilbutirato de glicerol genérico esté disponible a partir del 1 de julio de 2025, lo cual brindará opciones de medicamentos adicionales a médicos y pacientes. Tenga en cuenta que esta programación puede cambiar; Amgen no controla la fecha de disponibilidad de los medicamentos genéricos.

No es necesario realizar ninguna acción en este momento; sin embargo, es importante que usted o su ser querido estén al tanto de este posible cambio, ya que esperamos que con el tiempo, las compañías de seguros soliciten que los pacientes cambien a fenilbutirato de glicerol genérico.

Los medicamentos genéricos aprobados por la Administración de Alimentos y Medicamentos (FDA) de los Estados Unidos funcionan de la misma manera y brindan el mismo beneficio clínico que los medicamentos de marca. Los medicamentos genéricos pueden tener pequeñas diferencias que no afectan la eficacia ni la seguridad, pero vienen en envases diferentes.

En las próximas semanas, su Enlace de acceso para pacientes (Patient Access Liaison, PAL) de Amgen se comunicará con usted para brindarle recursos y más información. Amgen se compromete a brindarle a usted y a la comunidad de atención médica actualizaciones a medida que estén disponibles.

Si tiene alguna pregunta, no dude en comunicarse conmigo o con su PAL asignado.

Atentamente,

Jason Riley

Gerente General

Medicamentos Ultrararos

rareconnect@amgen.com